Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

311.72
-4.3600-1.38%
Pre-market: 311.720.00000.00%07:39 EDT
Volume:193.65K
Turnover:60.70M
Market Cap:18.76B
PE:33.84
High:316.68
Open:315.93
Low:311.37
Close:316.08
52wk High:330.75
52wk Low:263.00
Shares:60.18M
Float Shares:60.18M
Volume Ratio:1.10
T/O Rate:0.32%
Dividend:4.61
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.95
PE(LYR):7.51

Loading ...

UnitedHealth Adds Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

Reuters
·
Sep 24

UnitedHealth Group Announces Addition to Leadership Team

THOMSON REUTERS
·
Sep 24

UnitedHealth - Appoints Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

THOMSON REUTERS
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Health Canada Approves AbbVie’s Epkinly Combo for Relapsed or Refractory Follicular Lymphoma in Adults

Reuters
·
Sep 24

Epkinly® Receives Health Canada Approval for Adults with Follicular Lymphoma

THOMSON REUTERS
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24

RBC Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY)

TIPRANKS
·
Sep 24

RBC Capital Keeps Their Hold Rating on Merck & Company (MRK)

TIPRANKS
·
Sep 24

Johnson & Johnson (JNJ) Receives a Buy from RBC Capital

TIPRANKS
·
Sep 24

OpenAI agent hacked into Australia’s national healthcare system

CNN Business
·
Sep 24

Medtronic PLC Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24

Eli Lilly & Co. Stock Underperforms Wednesday When Compared to Competitors

Dow Jones
·
Sep 24